Clinical trials: Overactive Bladder (OAB)
Overactive Bladder
A Trial of Transcutaneous Nerve Stimulation for OAB
Overactive bladder causes urinary frequency, urgency and in some cases urgency incontinence. This study is testing the efficacy of transcutaneous tibial nerve stimulation (using skin patch electrodes via a transcutaneous…
- Trial name
- NCT02511717
- Testing
- Transcutaneous tibial nerve stimulation
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Overactive Bladder (OAB), Overactive Bladder Syndrome
Real-world Experiences and Voices Exploring the Actual Lived Burden of OAB: A Mixed-methods Multi-country PROMs Study on OAB Patients' Quality of Life
The main goal is to understand what it is truly like to live with OAB from the patient's perspective, including how it affects: daily activities, emotional wellbeing and mental health, social life and relationships, work and…
- Trial name
- REVEAL-OAB (NCT07545148)
- Volunteers
- 2,000 people
- Sponsor
- European Association of Urology Research Foundation
Urinary Urge Incontinence (UUI), Urinary Frequency (UF)
PMCF Study of the Axonics SNM System Model 5101 (R20) for the Indication of OAB
Post-market clinical follow-up for continued assessment of safety and performance to confirm long-term outcomes of the Axonics SNM System INS Model 5101.
- Conditions
- Urinary Urge Incontinence (UUI), Urinary Frequency (UF), Overactive Bladder (OAB)
- Trial name
- NCT06789406
- Testing
- Axonics SNM System INS Model 5101 (R20)
- Where
- 6 sites in United States, United Kingdom
- Volunteers
- 55 people
- Sponsor
- Axonics, Inc.
Urologic Diseases, Overactive Bladder Syndrome
Central Obesity in Cases of OAB
Obesity is not a homogeneous condition and that the regional distribution of adipose tissue is important to understanding the relation of obesity to disturbances in glucose and lipid metabolism.
- Conditions
- Urologic Diseases, Overactive Bladder Syndrome, Obesity, Abdominal
- Trial name
- NCT03750604
- Testing
- visceral fat obesity (surface area and function)
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Mansoura University
Urinary Bladder, Overactive
A Multicenter VESIcare® Efficacy and Safety Study for the Treatment of Urgency Associated With Overactive Bladder (OAB)
The purpose is to evaluate the efficacy of 5 and 10mg VESIcare® (solifenacin succinate) in patients with urgency who have overactive bladder syndrome.
- Trial name
- VENUS (NCT00454896)
- Testing
- VESIcare®
- Where
- 65 sites in United States
- Volunteers
- 739 people
- Sponsor
- Astellas Pharma Inc
Overactive Bladder, Neurogenic Detrusor Overactivity
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron Oral Suspension in Pediatric Subjects From 3 to Less Than 12 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB)
The purpose of the study is to evaluate the pharmacokinetics (PK) of mirabegron oral suspension after single dose administration in children with neurogenic detrusor overactivity (NDO) or overactive bladder (OAB).
- Trial name
- NCT02526979
- Testing
- mirabegron
- Where
- 3 sites in Denmark, Poland
- Volunteers
- 9 people
- Sponsor
- Astellas Pharma Europe B.V.
Urge Incontinence, Overactive Bladder (OAB)
A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder
The purpose of this study was to evaluate the efficacy of mirabegron for the treatment of overactive bladder (OAB) in Chinese participants.
- Trial name
- NCT04562090
- Testing
- mirabegron
- Where
- 15 sites in China
- Volunteers
- 249 people
- Sponsor
- Astellas Pharma China, Inc.
Overactive Bladder (OAB)
Non-invasive Saphenous Nerve Stimulation Therapy for Overactive Bladder
The goal of this clinical trial is to study the NiNA System and how it works to treat overactive bladder. Up to 290 participants will be enrolled in the study in the USA and Australia.
- Trial name
- NOVASTIM (NCT07780786)
- Testing
- Wearable neurostimulation system for saphenous nerve stimulation, tolterodine tartrate 4 mg extended release
- Where
- 2 sites in United States, Australia
- Volunteers
- 290 people
- Sponsor
- NinaMED Pty Ltd
Lower Urinary Tract Symptoms, Healthy
Electronic Urinary Flowmeter to Improve Accuracy of Bladder Diaries .
The goal of this clinical trial is to give an answer to the question of whether an automated calculation of voided volumes would produce a more accurate set of bladder diary data when compared to the traditional ''eye-balling''…
- Conditions
- Lower Urinary Tract Symptoms, Healthy, Overactive Bladder (OAB)
- Trial name
- e-BLaDR (NCT05702294)
- Testing
- Diary pod ( measuring vessel that automatically calculates voided volume)
- Where
- United Kingdom
- Volunteers
- 187 people, healthy volunteers welcome
- Sponsor
- Birmingham Women's and Children's NHS Foundation Trust
Overactive Bladder (OAB), Premature (Early) Ejaculation
Effect of Antimuscarinic Treatment on Premature Ejaculation Severity in Men With Overactive Bladder: a Prospective Comparison With Mirabegron
Overactive bladder (OAB) is a condition characterized by involuntary bladder contractions. Antimuscarinic drugs are commonly used to treat OAB by blocking muscarinic receptors (M2 and M3) in the bladder.
- Conditions
- Overactive Bladder (OAB), Premature (Early) Ejaculation, Ejaculation Abnormal
- Trial name
- NCT07736560
- Testing
- Tolterodine, Mirabegron (beta3-adrenoceptor agonist)
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- Başakşehir Çam & Sakura City Hospital
Spinal Vascular Disorder Nos, Overactive Bladder
Efficacy Comparison Between Different Management Strategies for Consistent OAB in Patients With SVMs After Surgery
The investigators' goal is to compare the efficacy of three different management strategies (sacral neuromodulation, botulinum toxin, M receptor antagonist) in treating consistent OAB in patients with SVMs after surgery.
- Trial name
- NCT03280316
- Testing
- surgery, sacral neuromodulation, botulinum toxin A injection
- Volunteers
- 100 people
- Sponsor
- Xuanwu Hospital, Beijing
Overactive Bladder (OAB)
Comparing Treatments for Overactive Bladder in Taiwan: A Study of Outcomes
Overactive bladder (OAB) syndrome is a prevalent condition that significantly impairs patients' quality of life. Standard therapeutic strategies include oral antimuscarinics (e.g., solifenacin), beta-3 adrenergic agonists (e.g.…
- Trial name
- NCT07025642
- Testing
- Urodynamic evaluation before and after solifenacin treatment., Urodynamic evaluation before and after mirabegron treatment., Urodynamic evaluation before and after combined treatment with solifenacin and mirabegron.
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Mackay Medical College
Overactive Bladder
Overactive Bladder (OAB) Voiding Diary and Urodynamics Correlation Study
This is a prospective cohort study study with the primary aim of identifying the strongest correlating parameters between voiding diaries and UDS studies most predictive for each type of urologic condition.
- Trial name
- NCT03473782
- Testing
- Voiding Diary, Urodynamics Correlation Study
- Where
- United States
- Volunteers
- 123 people
- Sponsor
- NYU Langone Health
Overactive Bladder (OAB), Lower Urinary Tract Dysfunction
Parasacral TENS Project
The purpose of the project is to compare the efficacy of parasacral transcutaneous electric nerve stimulation (TENS) versus standard second-line therapy (oral anticholinergics) for pediatric patients with overactive bladder (OAB)…
- Trial name
- NCT07892417
- Testing
- Parasacral transcutaneous electric nerve stimulation (TENS), Oxybutynin
- Volunteers
- 60 people
- Sponsor
- University of Virginia
Overactive Bladder
Study of ONO-8539 in Patients With Overactive Bladder
The objective of this study is to investigate efficacy, safety and tolerability of ONO-8539 in patients with overactive bladder.
- Trial name
- NCT00876421
- Testing
- Tolterodine, ONO-8539
- Where
- 50 sites in Czechia, Germany and 7 more
- Volunteers
- 435 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Overactive Bladder
Botox for the Treatment of Overactive Bladder Secondary to Benign Prostatic Obstruction
This is a prospective, randomized, double-blind study comparing intravesical injection of BOTOX to placebo. Study subjects will be randomized (1:1 ratio) to one of the following treatment groups:
- Trial name
- NCT01220726
- Testing
- Botox
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Overactive Bladder
Effects of Antimuscarinic Drugs on Overactive Bladder (OAB) Symptoms After Insertion of Ureteral Stents
The purpose of this study is to check whether antimuscarinics that usually broadly used in the treatment of overactive bladder symptoms are effective in the treatment of those symptoms after insertion of ureteral stents.
- Trial name
- NCT01210859
- Sponsor
- Meir Medical Center
Urinary Incontinence, Urgency-frequency, Overactive Bladder
InSite for Over Active Bladder
The purposes of this study are: 1. To provide evidence from a randomized controlled trial that InterStim Therapy provides better relief of symptoms of OAB than standard medical treatments in current use. 2.
- Trial name
- InSite - OAB (NCT00547378)
- Testing
- InterStim, Standard Medical Therapy
- Volunteers
- 571 people
- Sponsor
- MedtronicNeuro
Overactive Bladder, Urinary Incontinence
Study In Patients With Overactive Bladder Treated With Toviaz® After Failure Of Previous Therapy
This is a observational study in patients treated with fesoterodine (Toviaz), who have failed on previous treatment for overactive bladder.
- Trial name
- NCT00691093
- Testing
- fesoterodine
- Where
- 65 sites in Slovakia
- Volunteers
- 823 people
- Sponsor
- Pfizer
Overactive Bladder
A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo
A new drug for overactive bladder is compared to placebo to determine if it is safe and effective. The study lasts approximately 12 weeks.
- Trial name
- NCT00350636
- Testing
- Oxybutynin topical gel
- Where
- 63 sites in United States
- Volunteers
- 789 people
- Sponsor
- Watson Pharmaceuticals